Aytu Biopharma Inc - Understand $aytu stock

$AYTU Market Cap: $14.07 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$81.00M

TTM

Gross Margin

67.19%

TTM

Net Earnings

-$15.82M

TTM

Current Assets

$61.89M

Q2 2024

Current Liabilities

$62.23M

Q2 2024

Current Ratio

99.46%

Q2 2024

Total Assets

$118.1M

Q2 2024

Total Liabilities

$90.38M

Q2 2024

Book Value

$27.72M

Q2 2024

Cash

$20.01M

Q2 2024

P/E

-0.8893

Oct 16, 2024 EST

Free Cash Flow

Revenues

Revenue YoY Change

Revenues

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	$81.00M	$107.4M	$96.67M	$65.63M	$27.63M	$7.320M	$3.660M	$3.222M	$2.562M	$261.8K	$58.93K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-24.58%	11.1%	47.29%	137.52%	277.49%	100.0%	13.61%	25.72%	878.85%	344.23%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	$81.00M	$107.4M	$96.67M	$65.63M	$27.63M	$7.320M	$3.660M	$3.222M	$2.562M	$261.8K	$58.93K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$26.42M	$40.77M	$44.39M	$36.43M	$8.281M	$2.200M	$2.050M	$1.417M	$957.1K	$88.11K
Gross Profit	$54.59M	$66.63M	$52.28M	$29.20M	$19.35M	$5.120M	$1.610M	$1.804M	$1.605M	$173.7K
Gross Profit Margin	67.39%	62.04%	54.08%	44.49%	70.03%	69.95%	43.99%	56.0%	62.65%	66.34%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Selling, General & Admin	$49.47M	$70.08M	$69.88M	$55.81M	$31.06M	$19.24M	$17.73M	$17.44M	$8.518M	$3.981M	$60.00K	$50.00K	$60.00K	$130.0K	$60.00K	$60.00K	$60.00K	$50.00K
YoY Change	-29.4%	0.28%	25.22%	79.68%	61.43%	8.52%	1.65%	104.78%	113.96%	6534.96%	20.0%	-16.67%	-53.85%	116.67%	0.0%	0.0%	20.0%
% of Gross Profit	90.63%	105.17%	133.66%	191.12%	160.51%	375.78%	1101.24%	966.76%	530.57%	2292.22%
Research & Development	$2.791M	$4.095M	$14.44M	$5.623M	$1.722M	$590.0K	$170.0K	$959.9K	$6.128M	$3.219M	$3.934M
YoY Change	-31.84%	-71.64%	156.78%	226.54%	191.86%	247.06%	-82.29%	-84.34%	90.34%	-18.16%
% of Gross Profit	5.11%	6.15%	27.62%	19.26%	8.9%	11.52%	10.56%	53.2%	381.7%	1853.69%
Depreciation & Amortization	$8.272M	$8.815M	$10.25M	$9.201M	$5.714M	$2.730M	$2.590M	$4.365M	$874.8K	$118.2K	$97.48K	$0.00	$10.00K	$10.00K	$10.00K	$10.00K	$10.00K	$10.00K
YoY Change	-6.16%	-14.01%	11.41%	61.03%	109.3%	5.41%	-40.66%	398.94%	640.08%	21.26%		-100.0%	0.0%	0.0%	0.0%	0.0%	0.0%
% of Gross Profit	15.15%	13.23%	19.61%	31.51%	29.53%	53.32%	160.87%	241.91%	54.49%	68.06%
Operating Expenses	$59.84M	$83.70M	$163.8M	$88.07M	$40.48M	$21.97M	$19.45M	$23.35M	$24.27M	$7.200M	$3.934M	$50.00K	$60.00K	$130.0K	$60.00K	$60.00K	$60.00K	$50.00K
YoY Change	-28.5%	-48.92%	86.04%	117.55%	84.26%	12.96%	-16.69%	-3.79%	237.02%	83.05%	7767.24%	-16.67%	-53.85%	116.67%	0.0%	0.0%	20.0%
Operating Profit	-$5.254M	-$17.07M	-$111.6M	-$58.87M	-$21.13M	-$16.85M	-$17.84M	-$20.13M	-$21.70M	-$7.632M	-$6.347M
YoY Change	-69.21%	-84.7%	89.5%	178.6%	25.41%	-5.55%	-11.36%	-7.28%	184.37%	20.25%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Interest Expense	-$8.228M	$0.00	-$862.0K	-$2.050M	-$2.600M	-$450.0K	$3.230M	$2.534M	$5.491M	$115.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change		-100.0%	-57.95%	-21.15%	477.78%	-113.93%	27.45%	-53.85%	4675.45%
% of Operating Profit
Other Income/Expense, Net	$568.0K	$14.00K	$1.278M	$840.0K	$7.510M			-$2.383M	-$6.476M	-$115.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	3957.14%	-98.9%	52.14%	-88.81%				-63.2%	5531.33%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Pretax Income	-$14.08M	-$17.05M	-$110.3M	-$58.03M	-$13.62M	-$27.13M	-$10.19M	-$22.51M	-$28.18M	-$7.747M	-$6.392M	-$60.00K	-$60.00K	-$140.0K	-$60.00K	-$60.00K	-$60.00K	-$50.00K
YoY Change	-17.45%	-84.54%	90.04%	326.03%	-49.79%	166.24%	-54.73%	-20.12%	263.74%	21.2%	10553.98%	0.0%	-57.14%	133.33%	0.0%	0.0%	20.0%
Income Tax	$1.768M	$0.00	-$110.0K	$259.0K	$0.00		$0.00	$0.00	$0.00	-$23.91K	-$813.7K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$15.84M	-$17.10M	-$110.2M	-$58.29M	-$13.62M	-$27.13M	-$10.19M	-$22.51M	-$28.18M	-$7.723M	-$5.579M	-$60.00K	-$60.00K	-$140.0K	-$60.00K	-$60.00K	-$60.00K	-$50.00K
YoY Change	-7.35%	-84.48%	89.01%	327.93%	-49.79%	166.24%	-54.73%	-20.13%	264.87%	38.44%	9197.82%	0.0%	-57.14%	133.33%	0.0%	0.0%	20.0%
Net Earnings / Revenue	-19.56%	-15.92%	-113.97%	-88.81%	-49.29%	-370.63%	-278.42%	-698.67%	-1099.73%	-2950.32%	-9466.8%
Basic Earnings Per Share	-$2.86	-$5.11	-$3.39	-$3.48
Diluted Earnings Per Share	-$2.86	-$5.11	-$3.75	-$3.481M	-$3.013M	-$34.78M	-$145.6M	-$9.660B	-$64.74B	-$40.26B	-$6.840B	-$6.858B	-$7.248B	-$19.60B	-$10.09B	-$10.12B	-$9.844B	-$8.905B

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Cash & Short-Term Investments	$20.01M	$23.00M	$19.36M	$49.65M	$48.10M	$11.00M	$7.000M	$800.0K	$9.100M	$7.400M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-13.02%	18.8%	-61.01%	3.22%	337.27%	57.14%	775.0%	-91.21%	22.97%
Cash & Equivalents	$20.01M	$23.00M	$19.36M	$49.65M	$48.10M	$11.00M	$7.000M	$800.0K	$8.100M	$7.400M
Short-Term Investments								$0.00	$1.000M
Other Short-Term Assets	$5.635M	$8.900M	$8.008M	$11.07M	$11.70M	$1.300M	$500.0K	$400.0K	$300.0K	$500.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-36.69%	11.14%	-27.66%	-5.38%	800.0%	160.0%	25.0%	33.33%	-40.0%
Inventory	$12.63M	$12.00M	$10.85M	$16.34M	$10.00M	$1.400M	$1.300M	$1.300M	$500.0K	$0.00
Prepaid Expenses
Receivables	$23.62M	$28.90M	$21.71M	$28.18M	$5.600M	$1.700M	$600.0K	$500.0K	$200.0K	$200.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$61.89M	$72.80M	$59.93M	$105.2M	$75.40M	$15.40M	$9.500M	$3.000M	$10.10M	$8.000M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-14.98%	21.48%	-43.05%	39.57%	389.61%	62.11%	216.67%	-70.3%	26.25%
Property, Plant & Equipment	$1.522M	$3.900M	$6.296M	$8.703M	$900.0K	$200.0K	$200.0K	$600.0K	$200.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-60.97%	-38.06%	-27.66%	867.0%	350.0%	0.0%	-66.67%	200.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.229M	$800.0K	$766.0K	$465.0K	$0.00	$0.00	$0.00	$0.00	$200.0K	$300.0K	$0.00	$0.00
YoY Change	178.63%	4.44%	64.73%					-100.0%	-33.33%
Total Long-Term Assets	$56.20M	$63.70M	$77.69M	$160.4M	$77.90M	$19.30M	$11.60M	$12.00M	$14.20M	$10.20M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$100.0K	$100.0K
YoY Change	-11.77%	-18.01%	-51.57%	105.95%	303.63%	66.38%	-3.33%	-15.49%	39.22%							-100.0%	0.0%
Total Assets	$118.1M	$136.5M	$137.6M	$265.7M	$153.3M	$34.70M	$21.10M	$15.00M	$24.30M	$18.20M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$100.0K	$100.0K
YoY Change
Accounts Payable	$20.40M	$24.50M	$10.99M	$19.26M	$11.80M	$2.300M	$2.100M	$2.200M	$3.500M	$1.200M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-16.72%	122.99%	-42.94%	63.18%	413.04%	9.52%	-4.55%	-37.14%	191.67%
Accrued Expenses	$29.32M	$37.00M	$35.95M	$49.49M	$11.10M	$2.000M	$700.0K	$1.100M	$1.200M	$200.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-20.75%	2.93%	-27.36%	345.81%	455.0%	185.71%	-36.36%	-8.33%	500.0%
Deferred Revenue
YoY Change
Short-Term Debt	$2.395M	$1.600M	$3.813M	$7.934M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$0.00	$0.00
YoY Change	49.69%	-58.04%	-51.94%								-100.0%	0.0%	0.0%	0.0%	0.0%
Long-Term Debt Due	$1.857M	$100.0K	$96.00K	$16.67M	$0.00
YoY Change	1757.0%	4.17%	-99.42%
Total Short-Term Liabilities	$62.23M	$69.00M	$64.44M	$109.4M	$28.80M	$5.400M	$3.400M	$3.600M	$10.10M	$1.500M	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$0.00	$0.00
YoY Change	-9.81%	7.07%	-41.12%	279.99%	433.33%	58.82%	-5.56%	-64.36%	573.33%	1400.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Long-Term Debt	$10.88M	$14.70M	$14.28M	$180.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-26.01%	2.95%	7832.78%
Other Long-Term Liabilities	$17.27M	$13.40M	$12.81M	$18.48M	$29.50M	$22.30M	$4.200M	$7.400M	$4.200M	$1.100M
YoY Change	28.91%	4.61%	-30.69%	-37.35%	32.29%	430.95%	-43.24%	76.19%	281.82%
Total Long-Term Liabilities	$28.15M	$28.10M	$27.09M	$18.66M	$29.50M	$22.30M	$4.200M	$7.400M	$4.200M	$1.100M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	0.18%	3.73%	45.16%	-36.74%	32.29%	430.95%	-43.24%	76.19%	281.82%
Total Liabilities	$90.38M	$97.10M	$91.53M	$128.1M	$58.30M	$27.60M	$7.600M	$11.00M	$14.30M	$2.600M	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$0.00	$0.00
YoY Change	-6.92%	6.08%	-28.55%	119.73%	111.23%	263.16%	-30.91%	-23.08%	450.0%	2500.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2024	2023	2022	2021
Basic Shares Outstanding	5.538M	3.340M	29.40M	16.75M
Diluted Shares Outstanding		3.340M	29.40M	16.75M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $14.066 Million

About Aytu Biopharma Inc

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 150 full-time employees. The company went IPO on 2017-10-20. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.

Industry: Pharmaceutical Preparations Peers: /entities/agxrw Barrel Energy Inc Cingulate Inc Hoth Therapeutics Inc Jaguar Health Inc Johnson & Johnson Petros Pharmaceuticals, Inc. Pulmatrix Inc Weed Inc Virpax Pharmaceuticals Inc